Windward Bio Group AG, a Basel-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia. Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
VISCHER AG advises Kelun-Biotech, Harbour BioMed and RTW Investments in all Swiss law matters with Matthias Staehelin, Gian-Andrea Caprez, Vincent Reardon and Sandro Bernet (all Corporate/M&A).
Author: Gian-Andrea Caprez
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
